![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol. , 16 November 2022
Sec. Experimental Pharmacology and Drug Discovery
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1073543
This article is a correction to:
Polydeoxyribonucleotide, an Adenosine-A2A Receptor Agonist, Preserves Blood Testis Barrier from Cadmium-Induced Injury
A Corrigendum on:
Polydeoxyribonucleotide, an adenosine-A2A receptor agonist, preserves blood testis barrier from cadmium-induced injury
by Squadrito F, Micali A, Rinaldi M, Irrera N, Marini H, Puzzolo D, Pisani A, Lorenzini C, Valenti A, Laurà R, Germanà A, Bitto A, Pizzino G, Pallio G, Altavilla D and Minutoli L (2017). Front. Pharmacol. 7:537. doi: 10.3389/fphar.2016.00537
In the published article, the Conflict of Interest statement was incorrectly filed. The correct Conflict of Interest statement appears below.
“Author LM, FS, and AB are co-inventor on a patent describing therapeutic polydeoxyribonucleotide activity in testicular injury by torsion. Author FS has received research support from Mastelli for work on polydeoxyribonucleotide. Authors FS, AB, and DA are co-inventors on a patent describing therapeutic polydeoxyribonucleotide activity in chronic intestinal disease.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: cadmium, PDRN, blood-testis barrier, TGF-β3, pERK 1/2, TUNEL, immunohistochemistry, transmission electron microscopy
Citation: Squadrito F, Micali A, Rinaldi M, Irrera N, Marini H, Puzzolo D, Pisani A, Lorenzini C, Valenti A, Laurà R, Germanà A, Bitto A, Pizzino G, Pallio G, Altavilla D and Minutoli L (2022) Corrigendum: Polydeoxyribonucleotide, an adenosine-A2A receptor agonist, preserves blood testis barrier from cadmium-induced injury. Front. Pharmacol. 13:1073543. doi: 10.3389/fphar.2022.1073543
Received: 18 October 2022; Accepted: 19 October 2022;
Published: 16 November 2022.
Approved by:
Frontiers Editorial OfficeCopyright © 2022 Squadrito, Micali, Rinaldi, Irrera, Marini, Puzzolo, Pisani, Lorenzini, Valenti, Laurà, Germanà, Bitto, Pizzino, Pallio, Altavilla and Minutoli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Letteria Minutoli, bG1pbnV0b2xpQHVuaW1lLml0
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.